PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
23-Nov-2023 ASTRAZENECA SECURES NHS ACCESS TO IMFINZI▼(DURVALUMAB) IN COMBINATION WITH GEMCITABINE AND CISPLATIN IN ADVANCED BILIARY TRACT CANCER ACROSS ENGLAND AND WALES Astrazeneca
23-Nov-2023 EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK Edwards Lifesciences
23-Nov-2023 CellCentric’s inobrodib exhibits a novel mechanism of action with potential to treat a number of haematological malignancies: new data published in Cancer Cell CellCentric
21-Nov-2023 Pioneering Belgian project ATHENA paves the way for Real-World Data reuse in research and personalized care. ATHENA
21-Nov-2023 Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing Immix Biopharma, Inc.
21-Nov-2023 iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference iTeos
21-Nov-2023 Cherwell welcomes new recruits as pharma environmental monitoring needs grow Cherwell
21-Nov-2023 UK Medical Devices Regulations: TÜV Rheinland is now a UK Approved Body according to UK MDR TÜV Rheinland
21-Nov-2023 Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics Myricx Bio
21-Nov-2023 Vironova BioAnalytics AB Acquired by an investor syndicate, led by Quatre Lab, to expand its TEM services for the pharmaceutical industry; to be rebranded as QuTEM Vironova BioAnalytics
21-Nov-2023 EDX MEDICAL & THERMO FISHER SCIENTIFIC TO COLLABORATE ON DEVELOPMENT OF INNOVATIVE CANCER TESTS FOR GLOBAL MARKETS EDX Medical Group plc
21-Nov-2023 Kaleido launches cutting-edge Hybrid Closed Loop system with Diabeloop and Dexcom for people with diabetes ViCentra B.V.
21-Nov-2023 Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis Chiesi Group
21-Nov-2023 European Commission Approves pharmaand GmbH’s Rubraca® (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer pharmaand GmbH
20-Nov-2023 Landmark medicines deal to boost nation’s health, save NHS £14 billion, and support research investment Landmark medicines
20-Nov-2023 Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis Chiesi Group
20-Nov-2023 Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6 Omnix Medical
17-Nov-2023 CluePoints wins SCRIP Awards for Best Contract Research Organization (CRO): Specialist Providers CluePoints
17-Nov-2023 Symbio & Dow Group Merges with Proinnovera to Form Leading Dermatology CRO, Symbio Proinnovera Symbio & Dow Group / Proinnovera
16-Nov-2023 Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer Curium